CAS
NKTR icon

CTC Alternative Strategies’s Nektar Therapeutics NKTR Stock Holding History

CTC Alternative Strategies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,073
Closed -$9.26K – 153
2023
Q2 		$9.26K Buy
+1,073
New +$11.4K 0.01% 156

Other funds holding NKTR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

CTC Alternative Strategies's NKTR Position: Q3 2023 in Review

CTC Alternative Strategies sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 1,073 shares — an estimated $9.26K sold.

CTC Alternative Strategies first reported a position in NKTR in Q2 2023 and held it in 1 quarter. The position peaked at $9.26K in Q2 2023. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

  • CTC Alternative Strategies reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
  • CTC Alternative Strategies sold 1,073 Nektar Therapeutics shares in Q3 2023, an estimated $9.26K.
  • CTC Alternative Strategies first reported a position in Nektar Therapeutics in Q2 2023 and held it in 1 quarter.
  • CTC Alternative Strategies's Nektar Therapeutics position peaked at $9.26K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on CTC Alternative Strategies's 13F filing for Q3 2023, filed 31 Oct 2023.